Abstract
The molecular subtype of sporadic Creutzfeldt-Jakob disease (sCJD) is an important prognostic marker for patient survival. However, subtype determination is not possible during lifetime. Because the rate of disease progression is associated with the molecular subtype, this study aimed at investigating if total tau, a marker of neuronal death, allows premortem diagnosis of molecular subtype when codon 129 genotype is known. Two hundred ninety-six sCJD patients were tested for their cerebrospinal fluid total tau level at the time of diagnosis and were investigated for their sCJD subtype postmortem. There was a significant association between tau levels and the prion protein type in patients with codon 129 MM (p < 0.001), MV (p = 0.004), and VV (p = 0.001) genotype. Receiver operating characteristic analyses showed values of area under the curve of 0.76-0.80 for the different genotypes indicating a good diagnostic validity of the test. Total tau can be used as a diagnostic test for the assessment of prion protein type when codon 129 genotype is known. It provides valuable information for physicians and next of kin about the further course of disease.
References
Jan 24, 2002·Neurology·M OttoS Poser
Sep 28, 2005·Human Genetics·Gábor G KovácsUNKNOWN EUROCJD
May 3, 2007·Brain : a Journal of Neurology·U HeinemannI Zerr
Jul 10, 2007·Lancet Neurology·Bruno DuboisPhilip Scheltens
Mar 11, 2008·Neurobiology of Aging·K GmitterováI Zerr
Jun 10, 2009·Neurology·B MeissnerI Zerr
Sep 24, 2009·Brain : a Journal of Neurology·I ZerrP Sanchez-Juan
Jun 20, 2012·Lancet Neurology·Gianfranco PuotiPierluigi Gambetti
Citations
Apr 5, 2016·Annals of Clinical and Translational Neurology·Shorena JanelidzeOskar Hansson
Mar 27, 2016·Progress in Neurobiology·Franc LlorensInga Zerr
Apr 1, 2016·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·K GmitterováI Zerr
Oct 22, 2016·Journal of Alzheimer's Disease : JAD·André KarchInga Zerr
Nov 29, 2016·Annals of Neurology·Aaron FoutzJiri G Safar
Oct 28, 2017·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Piotr LewczukUNKNOWN Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato
May 7, 2019·JAMA Neurology·Adam M StaffaroniMichael D Geschwind
Jun 20, 2019·Neuropathology and Applied Neurobiology·F LlorensI Zerr
May 18, 2019·Journal of Neurology, Neurosurgery, and Psychiatry·Kaj BlennowFranc Llorens
Oct 1, 2017·Experimental and Therapeutic Medicine·Xingbang WangQun Zhang
Feb 3, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Inga ZerrFranc Llorens
Jul 3, 2020·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Franc LlorensInga Zerr
Nov 18, 2016·Aging·Matthias SchmitzInga Zerr
Jul 1, 2016·Journal of Neurology·M J LeitãoC R Oliveira
Dec 5, 2019·Biomolecules·Inga ZerrMatthias Schmitz
Nov 22, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Franc LlorensInga Zerr
Feb 17, 2017·Acta Neuropathologica·Francesca LattanzioPiero Parchi
Feb 21, 2021·Lancet Neurology·Peter HermannInga Zerr
Apr 23, 2021·Alzheimer's Research & Therapy·Inga ZerrFranc Llorens
Apr 22, 2021·Acta Neuropathologica·Daniela Diaz-LucenaFranc Llorens